Gamma-glutamyltransferase is a strong predictor of secondary sclerosing cholangitis after lung transplantation for COVID-19 ARDS.
Covid-19
critically ill patients
liver
lung transplantation
secondary sclerosing cholangitis
Journal
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
03
03
2022
revised:
20
06
2022
accepted:
24
06
2022
pubmed:
31
7
2022
medline:
5
10
2022
entrez:
30
7
2022
Statut:
ppublish
Résumé
Lung transplantation (LTx) can be considered for selected patients suffering from COVID-19 acute respiratory distress syndrome (ARDS). Secondary sclerosing cholangitis in critically ill (SSC-CIP) patients has been described as a late complication in COVID-19 ARDS survivors, however, rates of SSC-CIP after LTx and factors predicting this detrimental sequela are unknown. This retrospective analysis included all LTx performed for post-COVID ARDS at 8 European LTx centers between May 2020 and January 2022. Clinical risk factors for SSC-CIP were analyzed over time. Prediction of SSC-CIP was assessed by ROC-analysis. A total of 40 patients were included in the analysis. Fifteen patients (37.5%) developed SSC-CIP. GGT at the time of listing was significantly higher in patients who developed SSC-CIP (median 661 (IQR 324-871) vs 186 (109-346); p = 0.001). Moreover, higher peak values for GGT (585 vs 128.4; p < 0.001) and ALP (325 vs 160.2; p = 0.015) were found in the 'SSC' group during the waiting period. Both, GGT at the time of listing and peak GGT during the waiting time, could predict SSC-CIP with an AUC of 0.797 (95% CI: 0.647-0.947) and 0.851 (95% CI: 0.707-0.995). Survival of 'SSC' patients was severely impaired compared to 'no SSC' patients (1-year: 46.7% vs 90.2%, log-rank p = 0.004). SSC-CIP is a severe late complication after LTx for COVID-19 ARDS leading to significant morbidity and mortality. GGT appears to be a sensitive parameter able to predict SSC-CIP even at the time of listing.
Sections du résumé
BACKGROUND
Lung transplantation (LTx) can be considered for selected patients suffering from COVID-19 acute respiratory distress syndrome (ARDS). Secondary sclerosing cholangitis in critically ill (SSC-CIP) patients has been described as a late complication in COVID-19 ARDS survivors, however, rates of SSC-CIP after LTx and factors predicting this detrimental sequela are unknown.
METHODS
This retrospective analysis included all LTx performed for post-COVID ARDS at 8 European LTx centers between May 2020 and January 2022. Clinical risk factors for SSC-CIP were analyzed over time. Prediction of SSC-CIP was assessed by ROC-analysis.
RESULTS
A total of 40 patients were included in the analysis. Fifteen patients (37.5%) developed SSC-CIP. GGT at the time of listing was significantly higher in patients who developed SSC-CIP (median 661 (IQR 324-871) vs 186 (109-346); p = 0.001). Moreover, higher peak values for GGT (585 vs 128.4; p < 0.001) and ALP (325 vs 160.2; p = 0.015) were found in the 'SSC' group during the waiting period. Both, GGT at the time of listing and peak GGT during the waiting time, could predict SSC-CIP with an AUC of 0.797 (95% CI: 0.647-0.947) and 0.851 (95% CI: 0.707-0.995). Survival of 'SSC' patients was severely impaired compared to 'no SSC' patients (1-year: 46.7% vs 90.2%, log-rank p = 0.004).
CONCLUSIONS
SSC-CIP is a severe late complication after LTx for COVID-19 ARDS leading to significant morbidity and mortality. GGT appears to be a sensitive parameter able to predict SSC-CIP even at the time of listing.
Identifiants
pubmed: 35907758
pii: S1053-2498(22)02020-4
doi: 10.1016/j.healun.2022.06.020
pmc: PMC9249665
pii:
doi:
Substances chimiques
gamma-Glutamyltransferase
EC 2.3.2.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1501-1510Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure statement None of the authors have any relevant conflict of interest to declare.
Références
Lancet Respir Med. 2020 Oct;8(10):944-946
pubmed: 32857989
Am J Gastroenterol. 2007 Jun;102(6):1221-9
pubmed: 17531010
Clin Case Rep. 2018 Aug 02;6(9):1849-1853
pubmed: 30214777
N Engl J Med. 2022 Mar 24;386(12):1187-1188
pubmed: 35081299
Am J Gastroenterol. 2021 Jul 1;116(7):1414-1425
pubmed: 33993134
Hepatology. 2021 Jul;74(1):519-521
pubmed: 33226658
Ann Thorac Surg. 2007 Jan;83(1):257-63
pubmed: 17184674
Clin Exp Gastroenterol. 2017 Jun 23;10:105-111
pubmed: 28694703
Liver Int. 2021 Jan;41(1):20-32
pubmed: 33190346
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Endoscopy. 2008 Mar;40(3):214-8
pubmed: 18264887
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
J Hepatol. 2021 May;74(5):1243-1244
pubmed: 33617925
Endoscopy. 2012 Nov;44(11):1055-8
pubmed: 23108773
J Thorac Cardiovasc Surg. 2019 Jun;157(6):2515-2525.e10
pubmed: 30922636
Eur Respir J. 2022 Jun 30;59(6):
pubmed: 34824051
Lancet Respir Med. 2021 May;9(5):487-497
pubmed: 33811829
Clin Liver Dis. 2008 Feb;12(1):151-72, ix
pubmed: 18242502
BMJ Case Rep. 2021 Aug 26;14(8):
pubmed: 34446515
J Med Virol. 2021 Jan;93(1):102-104
pubmed: 32530522
Am J Transplant. 2022 Jan;22(1):144-153
pubmed: 34254423
BMJ Case Rep. 2014 Sep 30;2014:
pubmed: 25270153
Free Radic Res. 2004 Jun;38(6):535-9
pubmed: 15346644
Am J Gastroenterol. 2005 Jun;100(6):1330-3
pubmed: 15929765
Postgrad Med J. 2003 Jun;79(932):307-12
pubmed: 12840117
Crit Care. 2015 Mar 31;19:131
pubmed: 25886728
BMJ Case Rep. 2020 Nov 9;13(11):
pubmed: 33168538
Nat Rev Gastroenterol Hepatol. 2009 May;6(5):287-95
pubmed: 19404269
J Heart Lung Transplant. 2017 Oct;36(10):1097-1103
pubmed: 28942784
Hepatology. 2019 Dec;70(6):2204-2215
pubmed: 31215660
Intensive Care Med. 2021 Sep;47(9):1037-1040
pubmed: 34185115
Curr Opin Crit Care. 2006 Apr;12(2):160-5
pubmed: 16543794
Clin Gastroenterol Hepatol. 2021 Jun;19(6):1248-1257
pubmed: 32707342
Am J Gastroenterol. 2021 May 1;116(5):1077-1082
pubmed: 33464757
Clin Transplant. 2013 Sep-Oct;27(5):E563-70
pubmed: 23898897
Transplantation. 2021 Jun 1;105(6):1381-1387
pubmed: 33606480
JAMA. 2022 Feb 15;327(7):652-661
pubmed: 35085383
Eur J Med Res. 2012 Dec 22;17:30
pubmed: 23259907
Medicine (Baltimore). 2015 Dec;94(49):e2188
pubmed: 26656347
Mediterr J Hematol Infect Dis. 2022 Jan 01;14(1):e2022003
pubmed: 35070210